Market Overview

UPDATE: JP Morgan Downgrades Forest Laboratories to Neutral on Elongated Recovery

Related FRX
Icahn's (Potential) Move Into Biotech
Carl Icahn's Track Record In Big Pharma

JP Morgan downgraded Forest Laboratories (NYSE: FRX) from Overweight to Neutral and lowered its price target from $41 to $37.

JP Morgan said, "While Forest's development efforts have been highly successful and we see meaningful long-term term earnings power for the company, new product launches have lagged our expectations despite a significant ramp in SG&A. With a similar trend potentially repeating itself with several of the company's next-generation product opportunities, we believe Forest could see a more elongated recovery in earnings and along these lines, see better opportunities within our Specialty Pharma coverage."

Forest Laboratories closed at $33.40 on Wednesday.

Latest Ratings for FRX

May 2014UBSMaintainsNeutral
Apr 2014Cantor FitzgeraldMaintainsHold
Apr 2014SunTrust Robinson HumphreyDowngradesBuyNeutral

View More Analyst Ratings for FRX
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Downgrades Intraday Update Analyst Ratings


Related Articles (FRX)

View Comments and Join the Discussion!

Partner Center